arrow
P

Pere Barba

cell engineering and hematologic immunotherapy lab
H指数:41
被引数:6,385

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bridging therapy in pediatric and AYA patients under 25 years with relapsed/refractory B-ALL undergoing anti-CD19 CAR-T therapy: a multicenter retrospective study by the Spanish group GETH-TC

25岁以下复发/难治性B-ALL儿科及青少年成年过渡期患者接受抗CD19 CAR-T治疗时的桥接治疗:西班牙GETH-TC多中心回顾性研究

2026-10-120
PRE
Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy

巩固性同种异基因HCT与观察等待策略的比较:CAR T细胞治疗后早期丧失B细胞 aplasia的B细胞急性淋巴细胞白血病患者

2026-09-290
PRE
Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party

套细胞淋巴瘤患者中真实世界CAR-T实践模式:EBMT淋巴瘤工作组发起的一项国际调查

2026-08-180
PRE
Timing of Allogeneic Hematopoietic Cell Transplantation After Inotuzumab Ozogamicin Influences Sinusoidal Obstruction Syndrome and Survival in Relapsed/Refractory B-ALL

异基因造血细胞移植在奥佐米星之后的时机影响窦状阻塞综合征和复发/难治性B-ALL患者的生存

2026-08-150
PRE
EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study

EASIX在CAR T细胞疗法中不增加超过乳酸脱氢酶和ECOG体力状态 prognostic value:一项GETH-TC研究

2026-01-010
PRE
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry

全年龄段大剂量甲氨蝶呤:欧洲HDMTX登记研究的安全性、有效性与结局

Cancers
IF4.4
2025-12-310
OAAI
Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy

迈向个性化淋巴细胞清除:接受CAR T细胞疗法的患者群体药代动力学氟达拉滨模型

2025-12-100
OA
#3310 Long-term outcomes of patients developing acute kidney injury after CAR-T cell therapy for relapsed/refractory hematological malignancies

#3310 接受CAR-T细胞治疗复发/难治性血液系统恶性肿瘤后发生急性肾损伤患者的长期结局

2025-10-210
OA
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma

CD19 CAR-T在大型B细胞淋巴瘤中国际代谢预后指数的优化与验证

2025-08-260
OAAI
Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy

通过血清神经丝蛋白评估接受CD19靶向CAR T细胞疗法的ICANS患者中与严重程度相关的神经轴突损伤

2025-08-050
OAAI
Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials

在PETHEMA试验中治疗的成人T细胞急性淋巴细胞白血病患者的遗传进化和复发相关突变

2025-05-260
OA
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy

结外受累的大B细胞淋巴瘤的位点特异性分析揭示了嵌合抗原受体T细胞疗法的独特疗效

LEUKEMIA
IF13.4
2025-04-010
PRE
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

成人b细胞急性淋巴细胞白血病的Obecabtagene自体白血病

2024-12-120
PRE
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

大b细胞淋巴瘤患者在三线或更晚线治疗car-t进展后CAR预后指数的开发和验证

2024-10-290
OAAI
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO

老年患者的Anti-CD19 car-t细胞治疗: 来自GETH-TC/GELTAMO的多中心真实世界经验

2024-10-012
PRE
Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients
2024-08-282
OAAI
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials
2024-08-080
OAAI
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
2024-08-061
OAAI